Spyre Therapeutics logo

Spyre TherapeuticsNASDAQ: SYRE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 April 2016

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.73 B
-10%vs. 3y high
79%vs. sector
-vs. 3y high
-vs. sector
-2%vs. 3y high
89%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 58 min ago
$33.98+$1.45(+4.46%)

Dividend

No data over the past 3 years
$3.50 M$3.50 M

Analysts recommendations

Institutional Ownership

SYRE Latest News

Spyre Therapeutics Announces Grants of Inducement Awards
prnewswire.com01 November 2024 Sentiment: -

WALTHAM, Mass. , Nov. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 90,000 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
prnewswire.com14 October 2024 Sentiment: POSITIVE

SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025 New data on SPY003 presented at UEGW demonstrating robust preclinical activity including comparable potency and a greater than three-fold extension in half-life in NHPs relative to risankizumab1. Spyre portfolio now uniquely includes extended half-life molecules targeting α4β7, TL1A, and IL-23 with potential Q8W-Q12W maintenance dosing.

Spyre Therapeutics Announces Grants of Inducement Awards
prnewswire.com04 October 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Oct. 4, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of (i) stock options to purchase 400,000 shares of common stock of Spyre to Dr. Sheldon Sloan in connection with his appointment as Chief Medical Officer and (ii) stock options to purchase an aggregate of 129,000 shares of common stock of Spyre to four non-executive employees, in each case, as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
prnewswire.com01 October 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Sheldon Sloan, M.D.

Spyre Therapeutics to Participate in Upcoming Investor Conference
prnewswire.com10 September 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Sept. 10, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in a fireside chat and investor meetings at the Stifel 2024 Virtual Immunology and Inflammation Summit.

Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
prnewswire.com07 August 2024 Sentiment: POSITIVE

Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept data on track for year-end 2024 SPY002, an anti-TL1A antibody program designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing molecules, remains on track to begin first-in-human trials in the second half of 2024 Nominated a development candidate for SPY003, a highly potent anti-IL-23 antibody with an extended half-life compared to existing molecules, with expectations to begin a first-in-human trial in the first half of 2025 $426 million of cash, cash equivalents, marketable securities, and restricted cash as of June 30, 2024, with expected runway well into 2027, through multiple clinical readouts WALTHAM, Mass. , Aug. 7, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced its second quarter 2024 financial results and provided program and corporate updates.

Spyre Therapeutics Announces Grants of Inducement Awards
prnewswire.com03 June 2024 Sentiment: NEUTRAL

WALTHAM, Mass. , June 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 83,000 shares of common stock of Spyre to 3 non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").

Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher
Zacks Investment Research06 February 2024 Sentiment: POSITIVE

After losing some value lately, a hammer chart pattern has been formed for Spyre Therapeutics (SYRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

What type of business is Spyre Therapeutics?

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

What sector is Spyre Therapeutics in?

Spyre Therapeutics is in the Healthcare sector

What industry is Spyre Therapeutics in?

Spyre Therapeutics is in the Biotechnology industry

What country is Spyre Therapeutics from?

Spyre Therapeutics is headquartered in United States

When did Spyre Therapeutics go public?

Spyre Therapeutics initial public offering (IPO) was on 07 April 2016

What is Spyre Therapeutics website?

https://www.spyre.com

Is Spyre Therapeutics in the S&P 500?

No, Spyre Therapeutics is not included in the S&P 500 index

Is Spyre Therapeutics in the NASDAQ 100?

No, Spyre Therapeutics is not included in the NASDAQ 100 index

Is Spyre Therapeutics in the Dow Jones?

No, Spyre Therapeutics is not included in the Dow Jones index

When was Spyre Therapeutics the previous earnings report?

No data

When does Spyre Therapeutics earnings report?

The next expected earnings date for Spyre Therapeutics is 08 November 2024